AR051778A2 - Derivados del acido dimetilaminocrotonico y procesos para supreparacion - Google Patents
Derivados del acido dimetilaminocrotonico y procesos para supreparacionInfo
- Publication number
- AR051778A2 AR051778A2 ARP050104937A ARP050104937A AR051778A2 AR 051778 A2 AR051778 A2 AR 051778A2 AR P050104937 A ARP050104937 A AR P050104937A AR P050104937 A ARP050104937 A AR P050104937A AR 051778 A2 AR051778 A2 AR 051778A2
- Authority
- AR
- Argentina
- Prior art keywords
- supreparation
- derivatives
- processes
- dimethylaminocrotonic acid
- dimethylaminocrotonic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- External Artificial Organs (AREA)
- Quinoline Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) (CH3)2NCH2=(O)-OH o una sal HCl del mismo. Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, donde el compuesto es la sal HCl del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31064601P | 2001-08-07 | 2001-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051778A2 true AR051778A2 (es) | 2007-02-07 |
Family
ID=23203475
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102977A AR036250A1 (es) | 2001-08-07 | 2002-08-06 | Una combinacion antineoplasica, un producto que la comprende y el uso de dicha combinacion para la fabricacion de un medicamento para el tratamiento de un neoplasma en un mamifero |
ARP050104937A AR051778A2 (es) | 2001-08-07 | 2005-11-25 | Derivados del acido dimetilaminocrotonico y procesos para supreparacion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102977A AR036250A1 (es) | 2001-08-07 | 2002-08-06 | Una combinacion antineoplasica, un producto que la comprende y el uso de dicha combinacion para la fabricacion de un medicamento para el tratamiento de un neoplasma en un mamifero |
Country Status (27)
Country | Link |
---|---|
US (4) | US6617333B2 (es) |
EP (2) | EP1414438B1 (es) |
JP (2) | JP2005505549A (es) |
KR (1) | KR20040029406A (es) |
CN (3) | CN1326523C (es) |
AR (2) | AR036250A1 (es) |
AT (1) | ATE314069T1 (es) |
AU (2) | AU2002330994B2 (es) |
BR (1) | BR0211769A (es) |
CA (1) | CA2455126A1 (es) |
CY (1) | CY1104983T1 (es) |
DE (1) | DE60208385T2 (es) |
DK (1) | DK1414438T3 (es) |
EA (2) | EA006226B1 (es) |
ES (1) | ES2252512T3 (es) |
HK (1) | HK1061204A1 (es) |
HU (1) | HUP0401089A3 (es) |
IL (2) | IL159859A0 (es) |
MX (1) | MXPA04001118A (es) |
NO (2) | NO325503B1 (es) |
NZ (3) | NZ560845A (es) |
PL (1) | PL368303A1 (es) |
SG (1) | SG170612A1 (es) |
TW (2) | TWI305527B (es) |
UA (1) | UA77200C2 (es) |
WO (1) | WO2003020266A1 (es) |
ZA (1) | ZA200401801B (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
PT2269603E (pt) | 2001-02-19 | 2015-09-09 | Novartis Ag | Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano |
TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
EP1389209B1 (en) * | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
US20020198137A1 (en) * | 2001-06-01 | 2002-12-26 | Wyeth | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
JP4814520B2 (ja) * | 2002-05-15 | 2011-11-16 | エンドサイト,インコーポレイテッド | ビタミン−マイトマイシン結合体 |
US20040122048A1 (en) * | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
EP2517729A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
US20040258662A1 (en) * | 2003-04-22 | 2004-12-23 | Wyeth | Antineoplastic agents |
AU2004266572A1 (en) * | 2003-08-01 | 2005-03-03 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
AR046194A1 (es) | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
AR046639A1 (es) * | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
WO2005070393A2 (en) * | 2004-01-08 | 2005-08-04 | Wyeth | Directly compressible pharmaceutical composition of the rapamycin ester cci-779 |
RU2006127414A (ru) * | 2004-01-16 | 2008-02-27 | Вайет (Us) | Хинолиновые промежуточные соединения ингибиторов рецептора тирозинкиназы и их синтез |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
EP1789391B1 (en) * | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
EP1804779A1 (en) * | 2004-10-28 | 2007-07-11 | Wyeth | Use of an mtor inhibitor in treatment of uterine leiomyoma |
PL1848414T3 (pl) * | 2005-02-03 | 2011-10-31 | Wyeth Llc | Sposób leczenia nowotworu opornego na gefitinib |
CA2600675C (en) * | 2005-03-07 | 2015-12-15 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
WO2006101845A2 (en) * | 2005-03-16 | 2006-09-28 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
EP1883621A2 (en) * | 2005-05-25 | 2008-02-06 | Wyeth | Methods of preparing 3-cyano-quinolines and intermediates made thereby |
RU2007143161A (ru) * | 2005-05-25 | 2009-07-10 | Вайет (Us) | Способы синтеза замещенных 3-цианохинов и их продуктов |
JP2008542266A (ja) * | 2005-05-25 | 2008-11-27 | ワイス | 6−アルキルアミノキノリン誘導体の合成方法 |
MX2007016542A (es) * | 2005-06-24 | 2008-03-04 | Wyeth Corp | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer. |
BRPI0613574A2 (pt) * | 2005-07-01 | 2016-11-16 | Wyeth Corp | forma cristalina isolada de um composto, método para preparar um composto, e, composição farmacêutica |
CN103893778A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
JP2009504783A (ja) * | 2005-08-19 | 2009-02-05 | エンドサイト,インコーポレイテッド | ビンカアルカロイド、類似体および誘導体のリガンド結合体 |
PE20070763A1 (es) * | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
AU2013204788B2 (en) * | 2005-11-04 | 2016-12-08 | Wyeth Llc | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
AU2016259316B2 (en) * | 2005-11-04 | 2018-09-06 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272 |
SI2275103T1 (sl) * | 2005-11-21 | 2014-07-31 | Novartis Ag | mTor inhibitorji pri zdravljenju endokrinih tumorjev |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008121467A2 (en) * | 2007-02-28 | 2008-10-09 | Dana-Farber Cancer Institute, Inc. | Combination therapy for treating cancer |
EP2139523B1 (en) * | 2007-03-14 | 2014-10-22 | Endocyte, Inc. | Conjugates of folate and tubulysin for targeted drug delivery |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
BRPI0812970A2 (pt) * | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
AU2008316835B2 (en) | 2007-10-25 | 2015-07-16 | Endocyte, Inc. | Tubulysins and processes for preparing |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
CN102202667A (zh) | 2008-08-04 | 2011-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
EP2367535B1 (en) * | 2008-12-02 | 2017-02-22 | Biocompatibles Uk Ltd. | Pancreatic tumour treatment |
MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
PL2621903T3 (pl) | 2010-09-29 | 2017-08-31 | Intervet International B.V. | Związki n-heteroarylu |
EP2621923B1 (en) | 2010-09-29 | 2017-03-29 | Intervet International B.V. | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
MX2015004757A (es) | 2012-10-16 | 2015-07-17 | Endocyte Inc | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos. |
US10274503B2 (en) | 2013-05-08 | 2019-04-30 | Vegenics Pty Limited | Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis |
US9242965B2 (en) * | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
CA3228632A1 (en) | 2015-12-24 | 2017-06-29 | Kyowa Kirin Co., Ltd. | .alpha.,.beta.-unsaturated amide compound |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU415255A1 (ru) * | 1972-03-20 | 1974-02-15 | Т. А. Асонова, А. Я. Берлин, А. Б. Зезин, Е. Ф. Разводовский | СПОСОБ ПОЛУЧЕНИЯ р-БЕТАИ1ЮВВПТВci)iia aiisn^pii |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4194050A (en) | 1976-04-30 | 1980-03-18 | Sumitomo Chemical Company, Limited | Process for producing an enamide |
US4195021A (en) | 1977-10-26 | 1980-03-25 | Eli Lilly And Company | 1,3-Disubstituted 2-azetidinone antibitotics |
US4193983A (en) | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
BE897134A (fr) | 1983-06-24 | 1983-12-27 | Solvay | Dienes polysubstitues |
US4478959A (en) | 1983-09-29 | 1984-10-23 | Air Products And Chemicals, Inc. | Amino and amido divalent metal carboxylates useful as catalysts for polyurethane formulations |
DE3347659A1 (de) | 1983-12-31 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | Neue lackloesungen auf der basis von hydantoingruppen enthaltenden polymeren |
US4664825A (en) | 1984-10-25 | 1987-05-12 | The Lubrizol Corporation | Sulfurized compositions and lubricants containing them |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
AU634871B2 (en) | 1990-03-20 | 1993-03-04 | Banyu Pharmaceutical Co., Ltd. | Substituted amine derivatives having anti-hyperlipemia activity |
US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
CN1069492A (zh) * | 1991-08-21 | 1993-03-03 | 山之内制药株式会社 | 4-酰胺基咪唑衍生物 |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5352783A (en) | 1993-06-09 | 1994-10-04 | Merck & Co., Inc. | Microbial transformation product having immunosuppressive activity |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6664288B1 (en) * | 1999-04-14 | 2003-12-16 | Dana Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
ES2228932T3 (es) | 2000-08-11 | 2005-04-16 | Wyeth | Procedimiento de tratamiento del carcinoma positivo de estrogenos. |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
-
2002
- 2002-06-08 UA UA2004031662A patent/UA77200C2/uk unknown
- 2002-08-02 TW TW095110188A patent/TWI305527B/zh active
- 2002-08-02 TW TW091117467A patent/TWI300351B/zh active
- 2002-08-06 US US10/212,889 patent/US6617333B2/en not_active Ceased
- 2002-08-06 IL IL15985902A patent/IL159859A0/xx unknown
- 2002-08-06 NZ NZ560845A patent/NZ560845A/en unknown
- 2002-08-06 WO PCT/US2002/024841 patent/WO2003020266A1/en active Application Filing
- 2002-08-06 BR BR0211769-0A patent/BR0211769A/pt not_active IP Right Cessation
- 2002-08-06 CN CNB028153480A patent/CN1326523C/zh not_active Expired - Fee Related
- 2002-08-06 EP EP02768432A patent/EP1414438B1/en not_active Expired - Lifetime
- 2002-08-06 EP EP05019642A patent/EP1671943A1/en not_active Withdrawn
- 2002-08-06 CA CA002455126A patent/CA2455126A1/en not_active Abandoned
- 2002-08-06 HU HU0401089A patent/HUP0401089A3/hu unknown
- 2002-08-06 AR ARP020102977A patent/AR036250A1/es unknown
- 2002-08-06 EA EA200400284A patent/EA006226B1/ru not_active IP Right Cessation
- 2002-08-06 DE DE60208385T patent/DE60208385T2/de not_active Expired - Fee Related
- 2002-08-06 JP JP2003524573A patent/JP2005505549A/ja not_active Withdrawn
- 2002-08-06 ES ES02768432T patent/ES2252512T3/es not_active Expired - Lifetime
- 2002-08-06 NZ NZ530847A patent/NZ530847A/en unknown
- 2002-08-06 SG SG200600623-3A patent/SG170612A1/en unknown
- 2002-08-06 KR KR10-2004-7001883A patent/KR20040029406A/ko not_active Application Discontinuation
- 2002-08-06 MX MXPA04001118A patent/MXPA04001118A/es active IP Right Grant
- 2002-08-06 CN CNA2008100810681A patent/CN101279983A/zh active Pending
- 2002-08-06 CN CNB2006100025108A patent/CN100415753C/zh not_active Expired - Fee Related
- 2002-08-06 AT AT02768432T patent/ATE314069T1/de not_active IP Right Cessation
- 2002-08-06 NZ NZ542272A patent/NZ542272A/en unknown
- 2002-08-06 AU AU2002330994A patent/AU2002330994B2/en not_active Ceased
- 2002-08-06 EA EA200501251A patent/EA011098B1/ru not_active IP Right Cessation
- 2002-08-06 DK DK02768432T patent/DK1414438T3/da active
- 2002-08-06 PL PL02368303A patent/PL368303A1/xx unknown
-
2004
- 2004-01-14 IL IL159859A patent/IL159859A/en not_active IP Right Cessation
- 2004-02-06 NO NO20040558A patent/NO325503B1/no not_active IP Right Cessation
- 2004-03-04 ZA ZA200401801A patent/ZA200401801B/en unknown
- 2004-06-15 HK HK04104313A patent/HK1061204A1/xx not_active IP Right Cessation
-
2005
- 2005-09-08 US US11/222,485 patent/USRE40418E1/en not_active Expired - Lifetime
- 2005-11-25 AR ARP050104937A patent/AR051778A2/es unknown
-
2006
- 2006-02-22 CY CY20061100255T patent/CY1104983T1/el unknown
- 2006-10-24 AU AU2006233165A patent/AU2006233165B2/en not_active Ceased
- 2006-12-22 US US11/645,327 patent/USRE41084E1/en not_active Expired - Fee Related
-
2007
- 2007-07-20 NO NO20073801A patent/NO20073801L/no not_active Application Discontinuation
- 2007-10-26 US US11/978,093 patent/USRE41253E1/en not_active Expired - Lifetime
-
2010
- 2010-01-22 JP JP2010011652A patent/JP2010155845A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051778A2 (es) | Derivados del acido dimetilaminocrotonico y procesos para supreparacion | |
NO2022019I1 (no) | Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC | |
ATE297203T1 (de) | Antithrombotische mitteln | |
RS52625B (en) | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES | |
RS51444B (sr) | JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa | |
NO950297D0 (no) | Prolinamidderivater | |
ECSP044992A (es) | Inhibidores de la alquín-aril fosfodiesterasa-4 | |
CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
HRP20090281T1 (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
ATE326453T1 (de) | Antithrombotische amide | |
RS50140B (sr) | Postupak za dobijanje perkihinina i njegova upotreba | |
PT1307455E (pt) | Inibidores de adesao celular mediada por (alfa)l (beta)2 | |
MA27567A1 (fr) | Perindopril | |
CL2008003324A1 (es) | Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis. | |
ECSP045234A (es) | PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA | |
ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
ATE368645T1 (de) | Aminosäurederivate als hiv-protease-inhibitoren | |
DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
ECSP034561A (es) | Derivados puente de piperazina | |
ES2169242T3 (es) | 2-amino-benzoxazinonas para el tratamiento de infecciones virales. | |
EA200400214A1 (ru) | Азитромицин в виде разовой дозы | |
DE60114640D1 (en) | Antithrombosemittel | |
DK1204658T3 (da) | Benzofurylpiperazin-serotoninagonister | |
GB0212410D0 (en) | Organic compounds | |
DK1180094T3 (da) | Kondenserede polycykliske aminosyrer som farmaceutiske midler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |